Market Reacts Coolly to Teva's New Strategic Plan

Teva aims to reduce its expenses by $1.5 billion to $2 billion a year thanks to $1 billion to $1.2 billion cuts in its costs of sales.

comments Print

Since Jeremy Levin's appointment as CEO of Teva Pharmaceutical Industries at the beginning of last May, the company's stock has earned 1.6%, including...